Mobile Interpretation Bias Modification Clinical Trial (M-IBM)

May 26, 2022 updated by: University of Southern Mississippi
The Mobile-Interpretation Bias Modification clinical trial aims to examine the efficacy of a brief mobile phone delivered interpretation bias modification to reduce anxiety sensitivity cognitive concerns and suicidal ideation in National Guard Personnel. The investigators propose a randomized controlled trial testing the efficacy, acceptability, and usability of M-IBM with a sample of 114 National Guardsmen with current suicidal ideation and elevated anxiety sensitivity cognitive concerns. Participants will complete assessments, receive assistance on installing M- IBM on their phone, complete an M-IBM intervention session, and complete post-intervention assessments. Baseline measures of psychopathology, and usability/acceptability of M-IBM will be obtained during the initial session. In addition, 1-month, and 3-month follow-ups would be scheduled to examine changes in psychopathology. The investigators hypothesize that those randomized to M-IBM will experience reductions in anxiety sensitivity cognitive concerns, suicidal ideation. In addition participants will find M-IBM acceptable and easy to use.

Study Overview

Status

Enrolling by invitation

Study Type

Interventional

Enrollment (Anticipated)

114

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Mississippi
      • Hattiesburg, Mississippi, United States, 39406-0002
        • University of Southern Mississippi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Elevated ASCC (>2) and include only Guard members who also have current SI (> 0) .
  • Ownership of a smartphone

Exclusion Criteria:

  • those determined by military or study personnel to be actively psychotic, manic, or imminently suicidal and in need of emergency services

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: M-IBM
M-IBM is based on a slightly modified version of the word sentence association paradigm focused on words and sentences related to common concerns among those with elevated anxiety sensitivity cognitive concerns (i.e., losing control of mental processes).
In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be "unrelated" and the benign combinations as being "related" would produce a "correct" response. In contrast, if participants produce an "incorrect" response they see "incorrect".
PLACEBO_COMPARATOR: Control IBM
Control-IBM is identical to M-IBM except that the sentence that follows the cue word is not related to an anxious-threat interpretation of the cue word.
Placebo IBM where sentences are not related to anxious threat meaning of cue word.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anxiety Sensitivity Index-3 Cognitive Concerns Subscale
Time Frame: 30 minutes
Range 0 - 24, Higher Scores mean more pathology
30 minutes
Anxiety Sensitivity Index-3 Cognitive Concerns Subscale
Time Frame: 1 month post intervention
Range 0 - 24, Higher Scores mean more pathology
1 month post intervention
Anxiety Sensitivity Index-3 Cognitive Concerns Subscale
Time Frame: 3 months post intervention
Range 0 - 24, Higher Scores mean more pathology
3 months post intervention
The Self-Injurious Thoughts and Behaviors Interview
Time Frame: 1 month post intervention
1 month post intervention
The Self-Injurious Thoughts and Behaviors Interview
Time Frame: 3 months post intervention
3 months post intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 15, 2019

Primary Completion (ANTICIPATED)

March 29, 2023

Study Completion (ANTICIPATED)

March 29, 2023

Study Registration Dates

First Submitted

October 10, 2019

First Submitted That Met QC Criteria

October 15, 2019

First Posted (ACTUAL)

October 17, 2019

Study Record Updates

Last Update Posted (ACTUAL)

May 27, 2022

Last Update Submitted That Met QC Criteria

May 26, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • W81XWH-16-2-0004 (Other Grant/Funding Number: Military Suicide Research Consortium)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Suicidal Ideation

Clinical Trials on M-IBM

3
Subscribe